|
Summary Information: Kronos Bio Inc. Common Stock NASDAQ:KRON |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.
__The following are links to various summary and news pages for __Kronos Bio Inc. Common Stock [ KRON ]. __Note: Some Links might not have information for the company. |
|